Prohost BiotechResearch Platform
HomeArticlesCategoriesTagsSubscribe
Prohost BiotechResearch Platform

Advancing biotechnology through cutting-edge research, innovation, and scientific collaboration.

Platform

ArticlesCategoriesTags

Resources

About UsFAQContactPrivacy PolicyTerms & ConditionsCookie Policy

© 2026 Prohost Biotech. All rights reserved. Prohost Biotech is a registered trademark of Prohost Biotech.

Prohost BiotechResearch Platform
HomeArticlesCategoriesTagsSubscribe
Back to Categories

Impacting News

Timely updates on major biotech developments that could significantly influence the industry, markets, or investor sentiment. Focused on high-impact announcements, regulatory decisions, and breakthrough developments.

349 Articles
Impacting News
View:

Showing 1 to 12 of 349 articles in Impacting News

Impacting News
Premium

Axsome Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Total 1Q 2026 net product revenue of   $191.2 million, representing 57% year-over-year growth   AUVELITY ®   1Q 2026 net product sales of   $153.2 million, representing 59% year-over-year growth   SUN...
P

Prohost Biotech

May 6, 2026

1m
254
Impacting News
Premium

Neurocrine Biosciences Acquires Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio

Neurocrine ...
P

Prohost Biotech

Apr 8, 2026

1m
196
Impacting News
Premium

FDA Approved Lilly's Foundayo™ (orforglipron), the Only GLP-1 Pill for Weight Loss That Can Be Taken Any Time of Day Without Food or Water Restrictions

Eli Lilly in the NEWS INDIANAPOLIS, April 1, 2026 /PRNewswire/, Eli Lilly and Company ( LLY ) , announced the U.S. FDA approved Foundayo™ (orforglipron) for adults with obesity, or overweight with wei...
P

Prohost Biotech

Apr 2, 2026

1m
232
Impacting News
Premium

AstraZeneca’s Imfinzi Product Has Been Approved in the EU as the First and Only Perioperative Immunotherapy for Patients with Early Gastric and Gastroesophageal Cancers

AstraZeneca'a Imfinzi AstraZeneca ( AZN ) Imfinzi (durvalumab) in combination with standard-of-care FLOT chemotherapy (fluorouracil, leucovorin, oxaliplatin, docetaxel) has been approved in the Europe...
P

Prohost Biotech

Mar 20, 2026

1m
90
Impacting News
Premium

BridgeBio Pharma product BBP-418 Demonstrates Consistent Efficacy and Favorable Safety Profile in Phase 3 FORTIFY Interim Analysis in LGMD2I/R9

BridgeBio Pharma in the NEWS On March 11, 2026, BridgeBio Pharma ( BBIO ) presented additional positive data from the interim analysis of FORTIFY, the Phase 3 clinical trial of oral BBP-418, in indivi...
P

Prohost Biotech

Mar 12, 2026

1m
45
Impacting News
Premium

Mirum Pharmaceuticals Provides Enrollment Update for AZURE Clinical Program of Brelovitug in Chronic Hepatitis Delta Virus

Mirum Pharmaceuticals Mirum Pharmaceuticals ( MIRM ) is a leading rare disease company with a global footprint of approved products and a broad pipeline of investigational medicines. Purpose-built to...
P

Prohost Biotech

Mar 6, 2026

1m
59
Impacting News
Premium

FDA on Compounded Semaglutide and Teva Pharmacetuical and Blackstone Life Sciences Announce $400 Million Strategic Growth Capital Agreement to Advance Duvakitug

FDA on the Compounded Semaglutide  The FDA warns that compounded semaglutide is not FDA-approved, meaning it has not been reviewed for safety, effectiveness, or quality. Following the resolution of dr...
P

Prohost Biotech

Mar 4, 2026

1m
59
Impacting News
Premium

Johnson & Johnson Expands U.S. Footprint With More Than $1 Billion Investment In Next Generation Cell Therapy Manufacturing Facility in Pennsylvania

Johnson & Johnson in the NEWS Yesterday, February 18, 2026, Johnson & Johnson ( JNJ ) announced a more than $1 billion investment in a next generation cell therapy manufacturing facility in Montgomery...
P

Prohost Biotech

Feb 19, 2026

1m
58
Impacting News
Premium

Bio-Techne Corp Releases Second Quarter Fiscal 2026 Results

Bio-Techne Corp Q2 Financial Results Yesterday, February 4, 2026 /PRNewswire/ -- Bio-Techne Corporation ( TECH ) reported its financial results for the second quarter ending December 31, 2025. Second...
P

Prohost Biotech

Feb 5, 2026

1m
52
Impacting News
Premium

Corcept Therapeutics: Overall Survival Primary Endpoint Met In Pivotal Phase 3 Rosella Trial OF Relacorilant in Patients With Platinum-Resistant Ovarian Cancer

Corcept Therapeutics Yesterday, January 22, 2026,  Corcept Therapeutics ( CORT ) - a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, on...
P

Prohost Biotech

Jan 26, 2026

1m
46
Impacting News
Premium

Bristol-Myers Squibb Announces Collaboration with Microsoft to Advance AI-Driven Early Detection of Lung Cancer

Bristol-Myers Squibb and Microsoft Collaboration Bristol-Myers Squibb ( BMY )  - a global leader in oncology, announced an agreement with Microsoft, a market leader in AI-powered radiology and clinica...
P

Prohost Biotech

Jan 22, 2026

1m
63
Impacting News
Premium

GSK Enters Agreement to Acquire RAPT Therapeutics

GSK Agreement to Acquire RAPT Therapeutics Yesterday,  January 20, GSK ( GSK ) announced that it has entered a definitive agreement to acquire RAPT Therapeutics ( RAPT ) a California-based, clinical-s...
P

Prohost Biotech

Jan 21, 2026

1m
54
Showing 1 to 12 of 349 results
  • More pages
Prohost BiotechResearch Platform

Advancing biotechnology through cutting-edge research, innovation, and scientific collaboration.

Platform

ArticlesCategoriesTags

Resources

About UsFAQContactPrivacy PolicyTerms & ConditionsCookie Policy

© 2026 Prohost Biotech. All rights reserved. Prohost Biotech is a registered trademark of Prohost Biotech.